Anders Widmark

Alpha emitter radium-223 and survival in metastatic prostate cancer.

I Syndikus, J Kliment, S. Fosså, 2013, The New England journal of medicine.

The Prostate

Elin Thysell, A. Josefsson, P. Wikström, 2019 .

Expression of Androgen Receptor Splice Variants in Prostate Cancer Bone Metastases is Associated with Castration-Resistance and Short Survival

P. Stattin, H. Antti, A. Bergh, 2011, PloS one.

Nuclear androgen receptor staining in bone metastases is related to a poor outcome in prostate cancer patients.

O. Svensson, U. Lerner, A. Bergh, 2010, Endocrine-related cancer.

Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer

X. Breakefield, L. Mincheva-Nilsson, J. Skog, 2009, British Journal of Cancer.

Histopathology-validated lesion detection rates of clinically significant prostate cancer with mpMRI, [68Ga]PSMA-11-PET and [11C]Acetate-PET

J. Axelsson, K. Riklund, J. Jonsson, 2023, Nuclear medicine communications.

Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: Results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases.

N. James, A. Cross, Chris Parker, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Marked response to cabazitaxel in prostate cancer xenografts expressing androgen receptor variant 7 and reversion of acquired resistance by anti‐androgens

Elin Thysell, A. Josefsson, C. Thellenberg-Karlsson, 2019, The Prostate.

Histopathology-validated gross tumor volume delineations of intraprostatic lesions using PSMA-positron emission tomography/multiparametric magnetic resonance imaging

J. Axelsson, K. Riklund, J. Jonsson, 2024, Physics and imaging in radiation oncology.